Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (3434)	4/19/1998 3:20:00 PM
From: Dauntless	Read Replies (1) \| Respond to of 7041

Linda - back to the Fortune article. you posted <<<You yourself admitted today that you did not make any attempt to verify that the extensive story that Fortune printed was lifted from some rag where it was previously printed in December. You've admitted that you simply "heard "this was true, FAILED to make any attempt to verify it, but have continued to post it as if it's true even after admitting that you don't know for a fact whether it's true or not. You don't say in your subsequent posts that it might be true or that you heard it was true, you post <b.that it's true. As a result, I find your posting on this subject to be intentionally dishonest and misleading.>>> From the Centerwatch Web site for back issues(http://www.centerwatch.com/CW_ISSUE.HTM) ==================================================================== Volume 4, Issue 8 December 1, 1997 Article 72: AMCs Hope to Deliver with Integrated Healthcare Systems Summary As academic centers evolve into integrated healthcare systems, they envision providing sponsors with a broad range of drug-development services. Integrated systems boast of deep physician and patient resources. Leaders of major SMOs present opinions and predictions with regard to the involvement of integrated healthcare networks in clincial trials. Article 71 The Selling of Zonagen Summary Zonagen's sale of worldwide marketing rights for Vasomax to Schering-Plough is the latest step in this high-profile -- and somewhat controversial -- drug development story Article 70: Eye On: Allergy Summary CenterWatch editorial staff review new treatments in research for allergies and identify 30 investigational drugs in clinical development for this illness. =================================================================== It's $35 for back issues - I've read it, it's virtually identical to the Fortune article. You can order it simply enough. I can't post the content as it's copyrighted. Enough proof?? The existence of this article and it's content is not a "theory", "unproven concept", or "distortion of the truth" - it never was. This, as all of my posts, was based on facts - when I post theory I include "IMHO". Have a wonderful Sunday.